Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BYON3521 |
Synonyms | |
Therapy Description |
BYON3521 is an antibody-drug conjugate (ADC) comprising a Met-targeted monoclonal antibody linked to duocarmycin, which potentially results in antitumor activity against MET-expressing tumor cells (Cancer Res 2021;81(13_Suppl):Abstract nr 926). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BYON3521 | BYON-3521|BYON 3521 | MET Antibody 31 | BYON3521 is an antibody-drug conjugate (ADC) comprising a Met-targeted monoclonal antibody linked to duocarmycin, which potentially results in antitumor activity against MET-expressing tumor cells (Cancer Res 2021;81(13_Suppl):Abstract nr 926). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05323045 | Phase I | BYON3521 | A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521 | Active, not recruiting | NLD | ITA | GBR | BEL | 0 |